K. Kosovrasti

发表

HIV-1 Protease Inhibitors Incorporating Stereochemically Defined P2' Ligands to Optimize Hydrogen Bonding in the Substrate Envelope.

Nese Kurt Yilmaz, Celia A. Schiffer, Akbar Ali, 2019, Journal of medicinal chemistry.

Selection of HIV-1 for resistance to fifth-generation protease inhibitors reveals two independent pathways to high-level resistance

Shuntai Zhou, C. Schiffer, R. Swanstrom, 2019, bioRxiv.

pM to µM - Elucidating the Role of Distal Mutations in HIV-1 Protease in Conferring Drug Resistance.

Shuntai Zhou, C. Schiffer, D. Bolon, 2019, ACS chemical biology.

Structural Adaptation of Darunavir Analogs Against Primary Resistance Mutations in HIV-1 Protease

C. Schiffer, E. Nalivaika, Akbar Ali, 2018, bioRxiv.

Inhibiting HTLV-1 Protease: A Viable Antiviral Target.

C. Schiffer, E. Nalivaika, M. Somasundaran, 2021, ACS chemical biology.

Picomolar to Micromolar: Elucidating the Role of Distal Mutations in HIV ‑ 1 Protease in Conferring Drug Resistance

D. Bolon, R. Swanstrom, E. Nalivaika, 2019 .

Deciphering the Molecular Mechanism of HCV Protease Inhibitor Fluorination as a General Approach to Avoid Drug Resistance.

C. Schiffer, Akbar Ali, Adam K. Hedger, 2022, Journal of molecular biology.

Deciphering the Molecular Mechanism of HCV Protease Inhibitor Fluorination as a General Approach to Avoid Drug Resistance

C. Schiffer, E. Chan, Akbar Ali, 2021, bioRxiv.

Avoiding Drug Resistance by Substrate Envelope-Guided Design: Toward Potent and Robust HCV NS3/4A Protease Inhibitors

C. Schiffer, Akbar Ali, Adam K. Hedger, 2020, mBio.

Molecular and structural mechanism of pan-genotypic HCV NS3/4A protease inhibition by glecaprevir [preprint]

C. Schiffer, Akbar Ali, M. Henes, 2020 .

Molecular and structural mechanism of pan-genotypic HCV NS3/4A protease inhibition by glecaprevir

C. Schiffer, Akbar Ali, Nese Kurt-Yilmaz, 2019, bioRxiv.

Freestanding Emergency Department - A Stakeholder Study

K. Kosovrasti, A. Hu, An Brunelle, 2017 .

Structural Adaptation of Darunavir Analogues against Primary Mutations in HIV-1 Protease.

C. Schiffer, E. Nalivaika, Akbar Ali, 2018, ACS infectious diseases.

Assessing Human Immunodeficiency Virus (HIV) Protease Inhibition with Resistant Variants and Novel Inhibitors

M. Henes, K. Kosovrasti, 2018 .

HIV-1 protease inhibitors with a P1 phosphonate modification maintain potency against drug-resistant variants by increased interactions with flap residues.

C. Schiffer, R. Swanstrom, E. Nalivaika, 2023, European journal of medicinal chemistry.

Structural Analysis of Potent Hybrid HIV-1 Protease Inhibitors Containing Bis-Tetrahydrofuran in a Pseudo-Symmetric Dipeptide Isostere.

C. Schiffer, R. Swanstrom, E. Nalivaika, 2020, Journal of medicinal chemistry.

Molecular determinants of epistasis in HIV-1 protease: Elucidating the interdependence of L89V and L90M mutations in resistance.

C. Schiffer, D. Bolon, T. Whitfield, 2019, Biochemistry.

Molecular and structural mechanism of pan-genotypic HCV NS3/ Molecular and structural mechanism of pan-genotypic HCV NS3/ 4A protease inhibition by glecaprevir [preprint] 4A protease inhibition by glecaprevir [preprint] us you.

C. Schiffer, Akbar Ali, M. Henes, 2022 .